Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  >  CATEGORY RETURNS
CATEGORY RETURNS      
AMC : Category : Scheme :
Nippon India Pharma Fund(G)
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited12.221962563491067.7711
Domestic EquitiesDivi's Laboratories Limited7.54951000031659.5704
Domestic EquitiesLupin Limited5.92652683991517.7687
Domestic EquitiesCipla Limited5.69413200000497.4720
Domestic EquitiesDr. Reddy's Laboratories Limited5.69403916074497.4589
Domestic EquitiesApollo Hospitals Enterprise Limited5.5682648795486.4665
Domestic EquitiesMedPlus Health Services Limited3.86353627277337.5363
Domestic EquitiesVijaya Diagnostic Centre Limited3.55212886684310.3330
Domestic EquitiesGlaxoSmithKline Pharmaceuticals Limited3.3058913226288.8169
Domestic EquitiesGland Pharma Limited3.12101320549272.6670
Domestic EquitiesAjanta Pharma Limited3.0212959323263.9481
Domestic EquitiesAbbott India Limited2.704568677236.2832
Domestic EquitiesThyrocare Technologies Limited2.63131733833229.8889
Domestic EquitiesDr. Lal Path Labs Limited2.3771659112207.6796
Domestic EquitiesSai Life Sciences Limited2.36502555745206.6192
Domestic EquitiesNarayana Hrudayalaya Limited2.25621029215197.1153
Domestic EquitiesMankind Pharma Limited2.2259757496194.4644
Domestic EquitiesAurobindo Pharma Limited2.22131702630194.0658
Domestic EquitiesZydus Lifesciences Limited2.22082000632194.0213
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited2.0245999649176.8679
Domestic EquitiesPfizer Limited1.8922318249165.3144
Domestic EquitiesAlkem Laboratories Limited1.8640323678162.8456
Domestic EquitiesBiocon Limited1.77123953457154.7383
Domestic EquitiesSanofi India Limited1.5353230272134.1334
Domestic EquitiesSuraksha Diagnostic Limited1.34223896349117.2606
Domestic EquitiesIPCA Laboratories Limited1.3250785412115.7619
Domestic EquitiesTorrent Pharmaceuticals Limited1.2993303364113.5158
Domestic EquitiesSanofi Consumer Healthcare India Limited1.2003213659104.8638
Domestic EquitiesFortis Healthcare Limited1.0834110388994.6530
Domestic EquitiesSyngene International Limited1.0465128049291.4271
Domestic EquitiesAnthem Biosciences Limited0.9198105850380.3563
Domestic EquitiesAkums Drugs and Pharmaceuticals Limited0.9006151526478.6801
Domestic EquitiesEmcure Pharmaceuticals Limited0.758847027266.2895
Domestic EquitiesIndoco Remedies Limited0.6676183492458.3231
Domestic EquitiesAstraZeneca Pharma India Limited0.65796256857.4750
Domestic EquitiesOrchid Pharma Limited0.417649272736.4815
Domestic EquitiesConcord Biotech Limited0.226011173819.7475
Total 99.4519 8688.6814
Cash & Cash Equivalents and Net AssetsNet Current Assets0.2851 24.9071
Cash & Cash Equivalents and Net AssetsTriparty Repo0.2612 22.8198
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0018 0.1572
Total 0.5481 47.8841
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.